The FDA announced yesterday that it has approved two new suppliers for two critical cancer drugs that have experienced shortages, according to a Newsday report.
The FDA will temporarily allow a replacement drug for Doxil, a drug for ovarian and other cancers, to be imported. The drug has not been available to new patients for months. The FDA also approved a supplier for a preservative-free version of methotrexate, which is used to treat children with acute lymphoblastic leukemia and bone cancer.
Related Articles on Supply Chain:
Cardinal Health to Start Offering its Complete Portfolio of Surgical Gloves in Sustainable, Half-Fold Packaging
Teleflex Signs Agreement With HealthTrust for Arrow Intra-Aortic Balloon Pumps and Catheters
SourceMedical Launches Vision OnDemand Clinical and Business Management System for ASCs
The FDA will temporarily allow a replacement drug for Doxil, a drug for ovarian and other cancers, to be imported. The drug has not been available to new patients for months. The FDA also approved a supplier for a preservative-free version of methotrexate, which is used to treat children with acute lymphoblastic leukemia and bone cancer.
Related Articles on Supply Chain:
Cardinal Health to Start Offering its Complete Portfolio of Surgical Gloves in Sustainable, Half-Fold Packaging
Teleflex Signs Agreement With HealthTrust for Arrow Intra-Aortic Balloon Pumps and Catheters
SourceMedical Launches Vision OnDemand Clinical and Business Management System for ASCs